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Abstract 
Hodgkin lymphoma (HL) was one of the earliest 
cancers to be cured with multiagent chemotherapy 
even before its biology was understood.  
Over the past 50 years, a relevant progress has been 
made toward our understanding of HL pathology, 
cell biology and treatment options. Histologic 
classification of HL evolved through different 
systems, starting from the modern histologic 
classifications by Jackson and Parker in 1944 and 
Lukes and Collins in 1966, to the 2008 World Health 
Organization (WHO) classification.  Classical HL 
involves a clonal expansion of neoplastic B 
lymphocytes, though a small subset of cases may 
derive from T cells. Cure rates approaching 80% 
have been achieved in patients undergoing chemo-
radiotherapy, qualifying cHL as a chemosensitive 
disease. 
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Identity 
Other names: Hodgkin lymphoma, classical 
Hodgkin disease, Hodgkin disease 
Clinics and pathology 
Disease 
Hodgkin lymphoma(HL) has been classified into 
classical HL (cHL), which accounts for 95% of all 
HL cases, and the less common nodular lymphocyte 
predominant HL (NLPHL), which is considered to 
be a separate entity (Stein et al., 2008; Poppema et 
al., 2008). 
Classical HL is a distinct neoplastic entity with 
typical clinical, epidemiological, pathological, 
genetic, and virological features. It accounts for 
approximately 10% of all malignant lymphomas. 
Phenotype/cell stem origin 
Cell origin: Hodgkin and Reed-Sternberg (HRS) 
cells, the tumour cells of cHL, derive from 
preapoptotic crippled germinal center (GC) B cells. 
In fact, molecular features of HRS cells in cHL 
demonstrate that they are derived from GC B cells 
that have acquired disadvantageous immunoglobulin 
variable chain gene mutations and normally would 
have undergone apoptosis (Kuppers et al., 2012). 
As shown in gene expression profiling (GEP) 
studies, HRS cells have lost the expression of most 
B-cell genes and acquired expression of genes that 
are typical for other types of immune cells (Greaves 
and Gribben 2012; Steidl et al. 2012; Tiacci et al., 
2012). 
Phenotype: Phenotypically, HRS cells of cHL are 
consistently positive for CD30, CD15, CD40, and 
IRF4/MUM1 (Stein et al., 2008). 
Expression of molecular markers in cHL include 
(Younes et al., 2014) 
- B-cell markers (CD20 and CD79) usually negative 
- GC B-cell markers (BCL6 and AID) usually 
negative 
- Plasma cell markers (MUM1/IRF4) usually 
positive 
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- Molecules involved in Ag presentation (MHC class 
II, CD40, CD80, CD86) positive 
A surfaceoma study by TMA analysis indicated that 
gamma-glutamyltranspeptidase 1 is a potential 
additional marker for differential diagnosis of cHL 
versus non Hodgkin lymphoma (Hofmann et al., 
2015). 
Cellular components of the cHL microenvironment 
express molecules involved in cancer cell growth 
and survival (such as CD30L or CD40L), and in 
immune escape (programmed death 1 (PD-1). For 
example, CD30L+ eosinophils and mast cells, and 
proliferation-inducing ligand (APRIL)+ neutrophils, 
are consistently admixed to HRS cells, whereas 
CD40L-expressing CD4+ T lymphocytes rosette 
HRS cells. A fraction of infiltrating CD4+ T cells are 
regulatory T (Treg) cells. Treg cells and PD-1+ T 
cells also interact with HRS cells (Aldinucci et al., 
2010; Liu et al., 2014; Carbone et al., 2015). 
Epidemiology 
Classical HL is the most common cancer in patients 
under 20 years (adolescents and younger adults). The 
first peak of incidence can be observed in patients 
under 35 years of age, whereas a second incidence 
peak can be observed in the elderly (Hjalgrim et al, 
2008; Stein et al., 2008). 
Cytology 
Binucleated and multinucleated HRS cells are giant 
cells wirh bi- or multinucleation and huge nucleoli. 
These cells and their mononuclear variant, the so-
called Hodgkin cells, are pathognomonic for cHL 
identification. 
Pathology 
HRS cells reside in an inflammatory cell 
microenvironment. 
Based on the characteristics of the HRS cells 
(lacunar cells, multinucleated giant cells, 
pseudosarcomatous cells) and of the reactive 
infiltrate, four histologic subtypes have been 
distinguished: lymphocyte-rich cHL (LRCHL), 
nodular sclerosis (NS) cHL , mixed cellularity (MC) 
cHL , and lymphocyte depletion (LD) cHL . Most 
cHL can be classified as NS or MC subtypes. The 
remaining LRCHL and LD subtypes are uncommon. 
LRCHL cases display histological and clinical 
features intermediate between those of cHL and 
NLPHL (Poppema et al., 2008; Stein et al., 2008; 
Swerdlow et al., 2016). 
In cHL, microenvironmental cell types include T- 
and B-reactive lymphocytes, eosinophils, 
granulocytes, histiocytes/macrophages, plasma 
cells, mast cells. In addition, a great number of 
fibroblast-like cells and fibrosis are frequently found 
(Aldinucci et al., 2010). 
 
Figure 1. A multinucleated giant cell, the so called Reed-Sternberg cell.
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Figure 2. Mononucleated giant cells, the so called Hodgkin cells 
 
 
 
Figure 3. The schema shows a Reed-Sternberg within its cell microenvironment. 
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Other features 
 EBV infection 
The immunophenotypic and genetic features of HRS 
cells are identical in the different histologic subtypes 
of cHL. Conversely, the association with EBV 
shows differences. EBV is found in HRS cells 
preferentially in cases of MC and LD cHL, and less 
frequently in NS and LRCHL. Notably, EBV is 
found in HRS cells in nearly all cases of cHL 
occurring in patients infected with HIV (Younes et 
al., 2014; Dolcetti et al., 2016). 
The virologic characteristics of cHL vary according 
to the immunocompetence status of the host and cHL 
subtype (IARC, 2012) as follows: 
cHL of the general population 
- NS cHL, usually EBV negative 
- MC cHL, usually EBV positive 
- LRCHL, variably EBV positive 
- LD cHL, variably EBV positive 
Immunodeficiency-associated cHL 
- HIV-associated cHL, EBV positive 
- Post-transplant cHL, EBV positive 
- Iatrogenic (methotrexate), variaby EBV positive 
Treatment 
Cure rates approaching 80% have been achieved in 
patients undergoing chemo-radiotherapy, qualifying 
cHL as a chemosensitive disease (Santoro et al., 
1987, Canellos et al., 2014) . However, 25% to 30% 
of these patients show either primary refractoriness 
to chemotherapy, early disease relapse or late disease 
relapse (Canellos et al., 2014; Carbone et al., 2015). 
Prognosis 
The implementation of novel agents for the 
treatment of multi-relapsed cHL patients has 
improved the outcome of these patients and will 
significantly impact the history of multi-relapsed 
cHL in the near future when the results of 
combination studies become available. For example, 
the synergistic effect of 
Dehydroxymethylepoxyquinomicin (DHMEQ) with 
three chemotherapeutic drugs widely used in cHL 
treatment, doxorubicin, gemcitabine and cisplatin, 
has recently been demonstrated (Locatelli et al., 
2014). 
Genetics 
Recurrent genetic alterations have been identified in 
HRS cells of cHL. These lesions affecting members 
of the NF-kappaB or JAK/STAT signalling 
pathways include inactivating mutation in NFKBIA 
(10-20% of cases), NFKBIE (10%), TNFAIP3 
(40%), SOCS1 (40%), genomic gains of RELA 
(30%) and JAK2 (30%) and rare BCL3  
translocations. TNFAIP3 mutations are found in 
Epstein-Barr virus-negative cases of cHL. Mutations 
have been found in the tumour suppressor genes FAS 
(CD95) and TP53.  
Further genomic imbalances, identified by 
comparative genomic hybridization studies include 
gains of IKBKB, CD40 and MAP3K14 that are 
regulators of NF-kappaB signaling (Küppers and Re, 
2007; Hartmann et al., 2008; Steidl et al., 2010; 
Küppers 2011; Küppers et al., 2012; Pasqualucci and 
Dalla Favera, 2014). 
Interestingly, HRS cells show aberrant somatic 
hypermutation of several proto-oncogenes (PIM1, 
RHOH (TTF), MYC, PAX5) in a considerable 
fraction of cases (Küppers et al., 2012; Pasqualucci 
and  Dalla Favera, 2014). 
Cytogenetics 
HRS cells are clonal with variable modal 
chromosome numbers as indicated from direct 
chromosome analysis and DNA measurements and 
shown by the detection of clonal immunoglobulin V 
gene rearrangements in single HRS cells.  
The modes are about twice as frequently in the 
triploid-tetraploid as neardiploid region. 
Translocations involving the immunoglobulin loci 
have been found in about 20% of cHL; deletions and 
duplications, common in other types of tumour, have 
also been described in cHL.  
Diploid as well as aneuploid metaphases are 
commonly found in chromosome studies, both direct 
and after culturing. Using FISH 1-12% of "normal" 
nuclei in cHL exhibit abnormalities, especially 
trisomies for various chromosomes (Atkin, 1998; 
Jensen et al., 1998; Hartmann et al., 2008; Schmitz 
et al., 2009; Steidl et al., 2010; Küppers 2011). 
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